At a glance
ClinicalIndex Comparison RecordN/ACompleted· 730 enrolled
Drug / intervention
FIREHAWK biodegradable polymer rapamycin-eluting stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II
In Brief
A clinical study evaluating FIREHAWK biodegradable polymer rapamycin-eluting stent for Coronary Artery Disease. Completed, enrolled 730 participants across 1 site.
Detailed Summary
The study aims to further assess the safety, efficacy and the performance of its delivery system of FIREHAWK rapamycin-eluting stent up to five years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionFeb 2013
Study CompletionJan 2017
TodayJul 2026
First PostedAug 9, 2011
Enrollment StartAug 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.9 years ago
Interventions
FIREHAWK biodegradable polymer rapamycin-eluting stentdevice
DES PCI for CAD